Maravai LifeSciences Holdings, Inc. Stock News

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 18.42% and 10.81%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahea

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

They're risky. But they could also be huge winners.

Maravai LifeSciences (MRVI) acquired San Diego-based MyChem for $240M in cash with the potential for additional contingent cash based on achievement of certain conditions.Privately

Maravai LifeSciences went public in November 2020, raising $1.62 billion in gross proceeds in a U.S. IPO.

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators

Related Stocks: SBNY , UTHR , PANW , MRVI , ALB , CONE , TTD , BLMN , TFX , TWLO , FIVN , FL , OC , VFC ,

SAN DIEGO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that the Company has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to market open on Monday, December 20, 2021.

Strs Ohio lowered its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 15.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,000 shares of the companys stock after selling 26,600 shares during the period. Strs Ohio owned about []

Virginia Retirement Systems ET AL bought a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,300 shares of the companys stock, valued at approximately $800,000. Other institutional investors have []

Wall Street analysts expect that Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) will post $206.15 million in sales for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for Maravai LifeSciences earnings. The lowest sales estimate is $204.20 million and the highest is $208.70 million. Maravai LifeSciences posted sales of $98.35 million in the []

Cornerstone Investment Partners LLC decreased its position in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 19.7% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,895 shares of the companys stock after selling 1,200 shares during the period. Cornerstone Investment Partners []

Wall Street analysts expect Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) to announce earnings per share of $0.38 for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Maravai LifeSciences earnings, with the lowest EPS estimate coming in at $0.35 and the highest estimate coming in at $0.43. Maravai LifeSciences reported earnings per share []

Maravai LifeSciences Holdings, Inc. (MRVI) could be a solid addition to your portfolio given a notable revision in the company’s earnings estimates. While the stock has been gaining lately, the trend might continue since its earnings outlook is still improving. The rising trend in estimate revisions, which is a result of growing analyst optimism on […] The post Earnings Estimates Moving Higher for Maravai LifeSciences Holdings, Inc. (MRVI): Time to Buy? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

Maravai LifeSciences Holdings, Inc. (MRVI) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.